Sarilumab Trial for Melanoma
Phase 2
105
about 5.1 years
18–100
4 sites in CA, MA, NY
What this study is about
This trial is testing a new treatment called sarilumab, when combined with ipilimumab, nivolumab and relatlimab, in people with unresectable melanoma. The goal is to see if this combination can be safe, well-tolerated, and effective at treating the cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Ipilimumab Injection
- 2.Take Nivolumab/Relatlimab
- 3.Take Sarilumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ipilimumab (Immune checkpoint inhibitor; blocks CTLA-4 on T cells), nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells), Antineoplastic Agent [TC] (Antibody-Receptor Interactions), sarilumab
injection (Injection), infusion
Primary: Number of Grades 3-5 Treatment-Related Immune-Related Adverse Events (irAE) per NCI CTCAE v 5.0 Criteria
Secondary: Best overall response (iBOR), Disease Control Rate (DCR), Duration of Immune-related Overall Response, Duration of Overall Response, Immune-related Disease Control Rate per irRC criteria, Immune-related Progression-Free Survival (irPFS), Immune-related Response Rate (irRR) per irRC criteria, Overall survival (OS)
Oncology